Trial Profile

First-in-Human, single-dose, crossover, Phase I safety, tolerability, and pharmacokinetic study of AV104 buccal film and tablet

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nalmefene (Primary)
Indications Pruritus
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Avior Bio

Most Recent Events

08 Mar 2021 According to an Avior Bio media release, the company plans to complete this and another pharmacokinetic study in subjects with mild to moderate chronic liver disease. Completion of these studies will unable to finalize the design of phase II program in the treatment of chronic liver disease associated pruritus.
24 Jul 2020 New trial record
23 Jul 2020 According to an Avior Bio media release, the company will initiate first dose on Friday, July 24, 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com